RANDOMIZED, OPEN-LABEL, PHASE 2 STUDY OF SILTUXIMAB (AN ANTI-IL-6 MAB) AND BORTEZOMIB-MELPHALAN-PREDNISONE VERSUS BORTEZOMIB-MELPHALAN-PREDNISONE IN PATIENTS WITH PREVIOUSLY UNTREATED MULTIPLE MYELOMA
HAEMATOLOGICA(2013)
AI 理解论文
溯源树
样例
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要